All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 141 of 206 pages ‹ First < 139 140 141 142 143 > Last ›
HSL9692
Adverts broke MHRA rules
Pharmaceutical Journal 2004;272:(7298):564
HSL9696
650 million prescriptions dispensed in England last year
Pharmaceutical Journal 2004;272:(7297):533
HSL9697
Dickson M.
Key factors in the rising cost of new drug discovery and development
Nature Reviews Drug Discovery 2004;3:(5):417-429
HSL9698
Calcitonin intranasal - Unigene: Salcatonin intranasal - Unigene
Drugs in R and D 2004;5:(2):90-93
HSL9699
Patient group directions
MeReC Briefing 2004;(23):6-8
HSL9700
Supplementary prescribing
MeReC Briefing 2004;(23):1-6
HSL9701
Wechsler J.
McClellan moves to block counterfeits and require barcodes before leaving FDA
Pharmaceutical Technology Europe 2004;16:(4):17-21
HSL9702
Wechsler J.
Electronic information systems promote. Drug development and patient safety
Pharmaceutical Technology Europe 2004;16:(2):20-24
HSL9705
Blenkinsopp J.
Out of the dispensary and into the pharmacy - POM-to-P switching
Pharmaceutical Journal 2004;272:(7296):508-509
HSL9706
Approval for OTC statins
Pharmaceutical Journal 2004;272:(7296):497
HSL9707
Viagra "reward card" introduced in the US
Pharmaceutical Journal 2004;272:(7296):496
HSL9708
Part and parcel of change
Pharmaceutical Journal 2004;272:(7296):494
HSL9709
Motions for branch representatives' meeting
Pharmaceutical Journal 2004;272:(7295):487-490
HSL9710
Plan to allow prison officers to supply medicines
Pharmaceutical Journal 2004;272:(7295):466
HSL9713
Baeyens AJ.
Impact of the European Clinical Trials Directive on academic clinical research.
Med Law 2004;23:(1):103-10
HSL9714
Grubb D.
Promotion of over-the-counter medicines [8]
Australian Prescriber 2004;27:(2):33
HSL9715
Fusier I, Freville C, Tollier C, Husson MC.
Heterogeneous information on drug interactions: Review by a drug database editor for health practitioners
Journal de Pharmacie Clinique 2004;23:(1):25-30
HSL9716
Giraud C, Galene E, Begue D, Tixier C, Clement P.
Use and adverse events of nitrous oxide/oxygen 50/50 mol/mol analgesic mixture: Assessment of cohort temporary authorisation results of SOL France pharmaceutical establishment
Journal de Pharmacie Clinique 2004;23:(1):5-18
HSL9717
MHRA publicises changes to misleading advertisements
Pharmaceutical Journal 2004;272:(7294):440
HSL9719
Onohwosafe PS, Olaseha IO.
Factors influencing self-modication among students of Abadina College, Ibadan, Nigeria
International Journal of Health Promotion and Education 2004;42:(1):27-32
HSL9720
Minhas R.
OTC statins: The implications for primary prevention in the UK
British Journal of Cardiology 2004;11:(2):89-91
HSL9721
Peterson GM.
Risk factors - but only after excluding high-risk subjects
Pharmacoepidemiology and Drug Safety 2004;13:(4):253
http://www3.interscience.wiley.com/cgi-bin/abstract/106600330/ABSTRACT?SRETRY=0
HSL9722
Willy ME, Li Z.
What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling
Pharmacoepidemiology and Drug Safety 2004;13:(4):201-206
http://www3.interscience.wiley.com/cgi-bin/abstract/104530108/ABSTRACT
HSL9725
Improving systems should help to reduce errors due to look-alike and sound-alike drug names
Drugs and Therapy Perspectives 2004;20:(4):23-26
HSL9727
Pharmacy software with remote supervision capability launched
Pharmaceutical Journal 2004;272:(7293):405
HSL9728
Research and development costs: The great illusion. Response to Prescrire
Prescrire International 2004;13:(70):77-79
HSL9729
Industrial interests versus public health: The gap is growing
Prescrire International 2004;13:(70):71-76
HSL9730
Bubbles burst..
Prescrire International 2004;13:(70):70
HSL9731
No sartans during pregnancy
Prescrire International 2004;13:59
HSL9732
Nifuroxazide: New restrictions in children
Prescrire International 2004;13:(70):53
HSL9733
Why remove old but still valuable drugs?
Prescrire International 2004;13:(70):42
HSL9734
O'Connell B.
Medicare Reform and Health Savings Accounts: A Trojan Horse for Industry?
BioPharm International 2004;17:(4):24-26
HSL9736
Kumwenda L.
OTC products should be supplied in child resistant containers
Pharmaceutical Journal 2004;272:(7291):348
HSL9737
Lipitor is top seller worldwide
Pharmaceutical Journal 2004;272:(7291):344
HSL9739
Nash DB.
Follow-ups
P and T 2004;29:(3):
HSL9741
Kirby J.
Pharmacists must not overlook the opportunities on offer in animal health
Pharmaceutical Journal 2004;272:(7290):321-322
HSL9742
Cairns A.
Veterinary medicines - A challenge for the pharmacy profession to meet
Pharmaceutical Journal 2004;272:(7290):320
HSL9743
Alam MM.
We should give manufacturers the benefit of the doubt [10]
Pharmaceutical Journal 2004;272:(7289):281
HSL9744
Astbury FG, Mahaffy PJ.
Managing the risk of thalidomide (multiple letters)
Pharmaceutical Journal 2004;272:(7289):278-279
HSL9745
Kirby PM.
Back to the dark ages
Pharmaceutical Journal 2004;272:(7287):215
HSL9746
Pfizer helps pharmacists capitalise on health care market
Pharmaceutical Journal 2004;272:(7287):209
HSL9752
Wechsler J.
Pharmaceutical Pricing and Healthcare Access: Lead Policy Agenda
Pharmaceutical Technology 2004;28:(3):26-34
HSL9754
Government looks at instalment dispensing for benzodiazepines
Pharmaceutical Journal 2004;272:(7288):238
HSL9755
Harris KM, Devries A, Dimidjian K.
Trends in Naltrexone Use among Members of a Large Private Health Plan
Psychiatric Services 2004;55:(3):221
HSL9756
Tawab M.
Viagra from the Internet
Pharmazeutische Zeitung 2004;149:(9):43
HSL9757
Hollon MF.
Direct-to-consumer marketing of prescription drugs: a current perspective for neurologists and psychiatrists.
CNS Drugs 2004;18:(2):69-77
HSL9758
Thomson D, Capstick T.
How a risk management programme can ensure safety in thalidomide use
Pharmaceutical Journal 2004;272:(7286):190-191
HSL9760
Valaitis J, Peterson T.
Ethical Dilemmas: Scenario 3
Wisconsin Medical Journal 2004;103:(1):11-12
HSL9761
Bellingham C.
How to improve contraception services
Pharmaceutical Journal 2004;272:(7285):149-150
HSL9762
Patients should be able to buy Tamiflu, according to NPA
Pharmaceutical Journal 2004;272:(7285):146
HSL9764
Foran TM.
Choices in hormonal contraception
Medicine Today 2004;5:(2):30-37
HSL9765
Goldenberg MM.
Medicare and the New Generic Drug Legislation
P and T 2004;29:(2):89-94
HSL9767
Parvez N, Ahmed T, Monif T, Saha N, Sharma PL.
Comparative bioavailability of three oral formulations of sustained release theophylline in healthy human subjects
Indian Journal of Pharmacology 2004;36:(1):29-33
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=36&issue=1&spage=29
HSL9769
Law and ethics bulletin
Pharmaceutical-Journal 2004;272:(7282):70
HSL9770
Medicine adverts appeals process clarified
Pharmaceutical Journal 2004;272:(7282):48
HSL9771
European reforms will speed up access to new drugs
Pharmaceutical Journal 2004;272:(7282):47
HSL9772
Guidance for brand name prescriptions updated
Pharmaceutical Journal 2004;272:(7282):46
HSL9773
Preedy V, Mantle D.
Adverse effect on coenzyme Q10 levels [2]
Pharmaceutical Journal 2004;272:(7281):13
HSL9774
Bellingham C.
Is pharmacy ready for OTC statins?
Pharmaceutical Journal 2004;272:(7281):8-9
HSL9775
Spending rates for dementia drugs still vary
Pharmaceutical Journal 2004;272:(7281):
HSL9776
'Medicamentation' of society: An example of social pharmacology
Prescrire International 2004;13:(69):38
HSL9778
Lexchin J.
Are new drugs as good as they claim to be?
Australian Prescriber 2004;27:(1):2-3
HSL9782
Luggen ME.
Trials Are Short, Disease Long: Measuring Drug Utility Beyond Clinical Trials
Journal of Rheumatology 2004;31:(2):205-6
HSL9785
O'Connell B.
Going off Patent: Standing Pat or Getting Out
BioPharm International 2004;17:(1):26, 28
HSL9786
Wechsler J.
Medicare Bill Boosts Coverage for Biotech Therapies
BioPharm International 2004;17:(1):20, 22
HSL9788
Huang SM, Hall SD, Watkins P, Love LA, Serabjit-singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD.
Drug interactions with herbal products and grapefruit juice: A conference report
Clinical Pharmacology and Therapeutics 2004;71:(1):1-12
http://ezproxy.library.uq.edu.au/login?url=http://dx.doi.org/10.1016/j.clpt.2003.07.002
HSL9791
Barlas S.
Major Changes Ahead: Medicare Drug Benefit to Affect the Entire Drug-Distribution Chain
P and T 2004;29:(1):13
HSL9792
Nash DB.
Countering Counterfeiters
P and T 2004;29:(1):10-11
HSL9875
Pursuing a career in medical sales
Nature Reviews Drug Discovery 2004;3:(1):97-98
HSL9877
Circles to square on medicines
Veterinary Record 2004;154:(2):33
HSL9878
Calaf J, Ferrer M.
Pharmacological treatment of menopause in Spain in 2002
Clinica e Investigacion en Ginecologia y Obstetricia 2004;30:(9):299-306
HSL11251
Medawar C, Herxheimer A.
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
The International Journal of Risk and Safety in Medicine 2004;16:(1):5-19
http://iospress.metapress.com/app/home/contribution.asp?referrer=parent&backto=issue,3,8;journal,12,26;linkingpublicationresults,1:103162,1;
HSL11531
DiMasi JA, Paquette C.
The economics of follow-on drug research and development: trends in entry rates and the timing of development.
Pharmacoeconomics 2004;22:((2 Suppl 2)):1-14.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15660473
HSL11562
Grabowski H.
Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures
Pharmacoeconomics 2004;22:((2 Suppl 2)):15-24.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=15660474
HSL11628
Kauffman JM.
Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals
Journal of American Physicians and Surgeons Spring 2004;9:(1):11-14
http://www.jpands.org/vol9no1/kauffman.pdf
HSL12480
Phillips BJ, McQuarrie EF.
Beyond Visual Metaphor: A New Typology of Visual Rhetoric in Advertising
Marketing Theory 2004;4:(1-2):113-136
http://mtq.sagepub.com/cgi/content/abstract/4/1-2/113?ck=nck
HSL13552
von Hippel A
Better Health Care At Half The Cost
: Xlibris Corporation 2004
http://www2.xlibris.com/bookstore/bookdisplay.asp?bookid=24928
HSL14879
Ashcroft RE.
Current epistemological problems in evidence based medicine.
J Med Ethics 2004;30:131–135
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1733829&blobtype=pdf
HSL15098
Rasmussen N.
The Moral Economy of the Drug Company–Medical Scientist Collaboration in Interwar America
Social Studies of Science 2004;34:(2):161-185
http://sss.sagepub.com/cgi/content/abstract/34/2/161
HSL15100
Healy D.
Shaping the Intimate:: Influences on the Experience of Everyday Nerves
Social Studies of Science 2004;34:(2):219-245
http://sss.sagepub.com/cgi/content/abstract/34/2/219
HSL15542
Quick J, Dé A.
Update to the Direct-to-Consumer Debate: The Risks and Benefits of Pharmaceutical Promotion Across the Atlantic
Public Relations Strategist 2004;10:(2):29-31
http://www.prsa.org/publications/strategist/
HSL16338
Even P, Debré B
Savoir et Pouvoirs Paris: Le Cherche Midi 2004
http://www.eyrolles.com/Entreprise/Livre/savoirs-et-pouvoirs-9782749102498
HSL16341
Hadler N
The Last Well Person: How to stay well despite the health-care system. Montreal-Kingston: McGill-Queens University Press 2004
http://books.google.com.au/books?id=kTjV7urN8h8C&dq=Hadler,+Nortin.+The+Last+Well+Person:+How+to+stay+well+despite+the+health-care+system.&source=gbs_navlinks_s
HSL16346
Medawar C, Hardon A
Medicines out of Control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant 2004
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1079538
HSL16349
Saint-Onge JC
L’envers de la pilule: Les dessous de l’industrie pharmaceutique. Montréal: õcosociété 2004
http://www.livresquebecois.com/livre.asp?id=pzobfyugobfug&/l-envers-de-la-pilule-nouvelle-edition/jean-claude-st-onge
HSL16524
Kaiser T, Ewers H, Waltering A, Beckwermert D, Jennen C, Sawicki PT
Sind die Aussagen medizinischer Werbeprospekte korrekt?
Arznei Telegramm 2004;35:(21):3
www.di-em.de/data/at_2004_35_21.pdf
HSL16528
Huff-Rousselle M.
Book review: How to Develop and Implement a National Drug Policy.
Int J Health Plann Mgmt 2004;19:1–2
HSL16798
Glass HE.
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?
Dis Manag 2004 Spr;7:(1):77-87
http://www.liebertonline.com/doi/abs/10.1089/109350704322919014
HSL18036
Collier J
Regulating the regulators
Lancet 2004;363:(9427):2199-2199
http://linkinghub.elsevier.com/retrieve/pii/S014067360416529X
HSL18038
Spurgeon D
US junior doctors found to be ignorant of drug companies' tactics
BMJ 2004;328:(7447):1032
http://www.bmj.com/cgi/content/full/328/7447/1032-a
HSL18039
Harvey K
Website review: AdWatch web site
Aust Prescr 2004;27:(3):63
http://www.australianprescriber.com/index.php?content=/agazines/vol27no3/63_websitereview.htm
HSL18177
Fava GA
Conflict of Interest in Psychopharmacology: Can Dr. Jekyll Still Control Mr. Hyde?
Psychother Psychosom 2004;73:1-4
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000074433
HSL19046
Caudill-Slosberg MA, Schwartz LM, Woloshin S
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs.2000.
Pain 2004;109:(3):514-9
http://www.painjournalonline.com/article/S0304-3959(04)00130-7/abstract
HSL19387
Donohue JM, Berndt ER
Effects of direct-to-consumer advertising on medication choice: the case of anti-depressants
Journal of Public Policy & Marketing 2004;23:(2):115-127
http://www.kff.org/rxdrugs/upload/Effects-of-Direct-to-Consumer-Advertising-on-Medication-Choice-the-Case-of-Antidepressants.pdf
HSL19390
Manchanda P, Rossi P, Chintagunta P
Response modeling with nonrandom marketing-mix variables
J Marketing Res 2004;41:467–478
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=371360
HSL19286
Vadodara/ Bilaspur
Impoverishing the Poor: Pharmaceuticals and Drug Pricing in India : LOCOST/JSS 20040
http://www.scribd.com/my_document_collections/2879052
HSL19511
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one US medical school
Academic Medicine 2004;79:(11):1041-5
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=NxpFhX0RqlgMjcQZTwGJ3ngkLPpGZCNQPXqnKHLKYpXzVqQGgyhh!1776764395!181195628!8091!-1?issn=1040-2446&volume=79&issue=11&spage=1041
HSL19515
Light D, Lexchin J
Will lower drug prices jeoparidize drug research? A policy fact sheet
The American Journal of Bioethics 2004;4:(1):
http://bioethics.net/journal/j_articles.php?aid=61
HSL19918
Casey R
Designing Brand Identity: A Complete Guide to Creating, Building, and Maintaining Strong Brands
Journal of the Academy of Marketing Science 2004;23:(1):100-101
http://jam.sagepub.com/content/32/1/100.extract
HSL19974
The Evolving Environment For Prescription Drugs
Health Affairs 2004;23:(1):51
content.healthaffairs.org/content/23/1/51.full
Page 141 of 206 pages ‹ First < 139 140 141 142 143 > Last ›
